Sarah K Tasian

List of Publications by Year
in descending order

121 papers	5,719 citations	136950 32 h-index	82547 72 g-index
129 all docs	129 docs citations	129 times ranked	6920 citing authors

#	Article	IF	Citations
1	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2014, 371, 1005-1015.	27.0	1,161
2	JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9414-9418.	7.1	516
3	Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptorâ€“modified T cells. Blood, 2014, 123, 2343-2354.	1.4	396
4	Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood, 2012, 120, 3510-3518.	1.4	263
5	Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study. Blood, 2012, 119, 3512-3522.	1.4	210
6	Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood, 2012, 120, 833-842.	1.4	201
7	Philadelphia chromosomeâ€“like acute lymphoblastic leukemia. Blood, 2017, 130, 2064-2072.	1.4	198
8	Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood, 2015, 125, 1759-1767.	1.4	189
9	Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood, 2017, 129, 2395-2407.	1.4	148
10	Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood, 2017, 129, 177-187.	1.4	138
11	Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Science Translational Medicine, 2020, 12, .	12.4	117
12	Eradication of B-ALL using chimeric antigen receptorâ€“expressing T cells targeting the TSLPR oncoprotein. Blood, 2015, 126, 629-639.	1.4	110
13	Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Blood, 2013, 121, 4925-4929.	1.4	104
14	A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatric Blood and Cancer, 2015, 62, 1717-1724.	1.5	103
15	Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. Frontiers in Oncology, 2014, 4, 108.	2.8	92
16	CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Therapeutic Advances in Hematology, 2015, 6, 228-241.	2.5	89
17	Clinical utility of custom-designed NGS panel testing in pediatric tumors. Genome Medicine, 2019, 11, 32.	8.2	79
18	Clinical diagnostics and treatment strategies for Philadelphia chromosomeâ€“like acute lymphoblastic leukemia. Blood Advances, 2020, 4, 218-228.	5.2	69

#	Article	IF	Citations
19	Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics. British Journal of Haematology, 2017, 176, 867-882.	2.5	62
20	Childhood acute lymphoblastic leukemia: Integrating genomics into therapy. Cancer, 2015, 121, 3577-3590.	4.1	59
21	Influenzaâ€associated morbidity in children with cancer. Pediatric Blood and Cancer, 2008, 50, 983-987.	1.5	56
22	Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with <i>GOLGA5-JAK2</i> fusion and induction failure. Haematologica, 2018, 103, e427-e431.	3.5	56
23	Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?. Therapeutic Advances in Hematology, 2018, 9, 135-148.	2.5	53
24	Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia. Blood, 2017, 129, 3000-3008.	1.4	48
25	Histology of Testicular Biopsies Obtained for Experimental Fertility Preservation Protocol in Boys with Cancer. Journal of Urology, 2015, 194, 1420-1424.	0.4	46
26	Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood, 2022, 140, 619-629.	1.4	45
27	Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells. Leukemia, 2019, 33, 181-190.	7.2	43
28	Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. Oncotarget, 2018, 9, 8027-8041.	1.8	42
29	A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase. Blood, 2018, 132, 555-555.	1.4	42
30	Development and Clinical Validation of a Large Fusion Gene Panel for Pediatric Cancers. Journal of Molecular Diagnostics, 2019, 21, 873-883.	2.8	41
31	Understanding the Biology of CRLF2-Overexpressing Acute Lymphoblastic Leukemia. Critical Reviews in Oncogenesis, 2011, 16, 13-24.	0.4	39
32	Aberrant splicing in B-cell acute lymphoblastic leukemia. Nucleic Acids Research, 2018, 46, 11357-11369.	14.5	39
33	Induction mortality and resource utilization in children treated for acute myeloid leukemia at freeâ€standing pediatric hospitals in the United States. Cancer, 2013, 119, 1916-1923.	4.1	37
34	A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study. Blood Advances, 2019, 3, 1330-1346.	5.2	36
35	Molecular Therapeutic Approaches for Pediatric Acute Myeloid Leukemia. Frontiers in Oncology, 2014, 4, 55.	2.8	35
36	Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. Blood, 2021, 138, 1465-1480.	1.4	34

#	Article	IF	Citations
37	A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114). British Journal of Haematology, 2017, 177, 467-474.	2.5	32
38	Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies. Blood Cancer Discovery, 2022, 3, 103-115.	5.0	31
39	Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory Bâ€acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2021, 68, e28718.	1.5	30
40	Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL. Journal of Clinical Investigation, 2020, 130, 3637-3653.	8.2	30
41	Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches. Cancer Immunology, Immunotherapy, 2009, 58, 1257-1264.	4.2	29
42	Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. Oncogene, 2019, 38, 2241-2262.	5.9	29
43	Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. , 2021, 9, e003149.		28
44	Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia. Frontiers in Pediatrics, 2017, 5, 248.	1.9	25
45	Opportunities for immunotherapy in childhood acute myeloid leukemia. Blood Advances, 2019, 3, 3750-3758.	5.2	25
46	Molecular and phenotypic diversity of <I>CBL</I>-mutated juvenile myelomonocytic leukemia. Haematologica, 2022, 107, 178-186.	3.5	25
47	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer. European Journal of Cancer, 2022, 160, 112-133.	2.8	24
48	Direct long-read RNA sequencing identifies a subset of questionable exitrons likely arising from reverse transcription artifacts. Genome Biology, 2021, 22, 190.	8.8	20
49	CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2022, 40, 252-261.	1.6	18
50	Preclinical Development of FLT3-Redirected Chimeric Antigen Receptor T Cell Immunotherapy for Acute Myeloid Leukemia. Blood, 2016, 128, 1072-1072.	1.4	17
51	How is the Ph-like signature being incorporated into ALL therapy?. Best Practice and Research in Clinical Haematology, 2017, 30, 222-228.	1.7	16
52	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discovery, 2021, 11, 1424-1439.	9.4	16
53	Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice. Leukemia, 2022, 36, 42-57.	7.2	16
54	Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia. Haematologica, 2021, 106, 1067-1078.	3.5	15

#	Article	IF	Citations
55	mTOR inhibition enhances efficacy of dasatinib in <i>ABL</i>-rearranged Ph-like B-ALL. Oncotarget, 2018, 9, 6562-6571.	1.8	15
56	Targeting Leukemia Stem Cells in the Bone Marrow Niche. Biomedicines, 2018, 6, 22.	3.2	14
57	Diverse noncoding mutations contribute to deregulation of cis-regulatory landscape in pediatric cancers. Science Advances, 2020, 6, eaba3064.	10.3	14
58	Efficient Termination of CD123-Redirected Chimeric Antigen Receptor T Cells for Acute Myeloid Leukemia to Mitigate Toxicity. Blood, 2015, 126, 565-565.	1.4	14
59	The future of cellular immunotherapy for childhood leukemia. Current Opinion in Pediatrics, 2020, 32, 13-25.	2.0	13
60	Therapeutic potential of ruxolitinib and ponatinib in patients with <i>EPOR</i>-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia. Haematologica, 2021, 106, 2763-2767.	3.5	12
61	Generation of a human Juvenile myelomonocytic leukemia iPSC line, CHOPi001-A, with a mutation in CBL. Stem Cell Research, 2018, 31, 157-160.	0.7	11
62	Diagnostic Challenges in Pediatric Hemophagocytic Lymphohistiocytosis. Journal of Clinical Immunology, 2021, 41, 1213-1218.	3.8	10
63	Development of Anaplastic Wilms Tumor and Subsequent Relapse in a Child With Diaphanospondylodysostosis. Journal of Pediatric Hematology/Oncology, 2012, 34, 548-551.	0.6	9
64	Labial Ecthyma Gangrenosum in an Immunocompromised Infant With Leukemia: Heightening Awareness for the Urologist. Urology, 2012, 80, 1366-1368.	1.0	9
65	Improved surfaceome coverage with a labelâ€free nonaffinityâ€purified workflow. Proteomics, 2017, 17, 1600344.	2.2	9
66	Anti-CD123 Chimeric Antigen Receptor T Cells (CART-123) Provide A Novel Myeloablative Conditioning Regimen That Eradicates Human Acute Myeloid Leukemia In Preclinical Models. Blood, 2013, 122, 143-143.	1.4	9
67	Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosomeâ€"Like Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2021, 27, 5109-5122.	7.0	8
68	Capturing the complexity of the immune microenvironment of acute myeloid leukemia with 3D biology technology.. Journal of Clinical Oncology, 2018, 36, 50-50.	1.6	8
69	Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001). Haematologica, 2022, 107, 2295-2303.	3.5	8
70	Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Blood, 2019, 134, 459-459.	1.4	6
71	Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group. Blood, 2020, 136, 45-46.	1.4	6
72	Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?. Best Practice and Research in Clinical Haematology, 2021, 34, 101331.	1.7	6

#	Article	IF	Citations
73	In Vivo Efficacy of PI3K Pathway Signaling Inhibition for Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia. Blood, 2013, 122, 2672-2672.	1.4	5
74	mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALL. Blood, 2016, 128, 2763-2763.	1.4	5
75	Thymic Stromal Lymphopoietin Stimulation of Pediatric Acute Lymphoblastic Leukemias with CRLF2 Alterations Induces JAK/STAT and PI3K Phosphosignaling. Blood, 2010, 116, 410-410.	1.4	4
76	Potent Efficacy of Combined PI3K/mTOR and JAK or SRC/ABL Inhibition in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia. Blood, 2015, 126, 798-798.	1.4	4
77	Adaptive Reactivation of Signaling Pathways As a Novel Mechanism of Resistance to JAK Inhibitors in Ph-like ALL. Blood, 2016, 128, 755-755.	1.4	4
78	Mixed Phenotype Acute Leukemia with Low Hypodiploidy in a Pediatric Patient. Journal of Pediatric Oncology, 2015, 3, 24-28.	0.1	4
79	Targeted therapy or transplantation for paediatric ABL-class Ph-like acute lymphocytic leukaemia?. Lancet Haematology,the, 2020, 7, e858-e859.	4.6	3
80	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium. Blood, 2018, 132, 261-261.	1.4	3
81	Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia. Blood, 2015, 126, 2529-2529.	1.4	3
82	Redundant JAK, SRC and PI3 Kinase Signaling Pathways Regulate Cell Survival in Human Ph-like ALL Cell Lines and Primary Cells. Blood, 2017, 130, 717-717.	1.4	3
83	Targeting Leukemia Stem Cells and the Immunological Bone Marrow Microenvironment. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 153-172.	0.1	2
84	Abstract 1630: FLT3 chimeric antigen receptor T cell therapy induces B to T cell lineage switch in infant acute lymphoblastic leukemia. , 2018, , .		2
85	Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123Ã—CD3 Bispecific DartÂ® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2019, 134, 460-460.	1.4	2
86	DYRK1A Is Required to Alleviate Replication Stress in KMT2A-Rearranged Acute Lymphoblastic Leukemia. Blood, 2020, 136, 39-40.	1.4	2
87	Evaluating on-Target Toxicity of Hematopoietic-Targeting Cars Demonstrates Target-Nonspecific Suppression of Marrow Progenitors. Blood, 2016, 128, 3357-3357.	1.4	2
88	Temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukemia (ALL): A Childrenâ€™s Oncology Group study.. Journal of Clinical Oncology, 2015, 33, 10029-10029.	1.6	2
89	An Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in Acute Myeloid Leukemia. Blood, 2020, 136, 26-27.	1.4	2
90	Transient atypical monocytosis after Î±/Î² Tâ€cellâ€depleted haploidentical hematopoietic stem cell transplantation. Pediatric Blood and Cancer, 2020, 67, e28139.	1.5	1

#	Article	IF	Citations
91	Dual Targeting of JAK2 Signaling with a Type II JAK2 Inhibitor and of mTOR with a TOR Kinase Inhibitor Induces Apoptosis in CRLF2-Rearranged Ph-like Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3706-3706.	1.4	1
92	A phase I study of ruxolitinib in children with relapsed/refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group Phase I Consortium study (ADVL1011).. Journal of Clinical Oncology, 2014, 32, 10019-10019.	1.6	1
93	Matched targeted therapy for pediatric patients with relapsed, refractory or high-risk leukemias: A report from the LEAP consortium.. Journal of Clinical Oncology, 2018, 36, 10518-10518.	1.6	1
94	Targeting mTOR and JAK2 in Xenograft Models of CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL). Blood, 2011, 118, 249-249.	1.4	1
95	Targeted Therapy and Precision Medicine. , 2017, , 183-200.		1
96	Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL. Blood, 2019, 134, 747-747.	1.4	1
97	Opportunities for immunotherapy in childhood acute myeloid leukemia. Hematology American Society of Hematology Education Program, 2019, 2019, 218-225.	2.5	1
98	Clinical significance of serial tumor next generation sequencing (NGS) in 155 pediatric cancer patients.. Journal of Clinical Oncology, 2020, 38, e13666-e13666.	1.6	1
99	Temsirolimus combined with etoposide and cyclophosphamide for relapsed/refractory acute lymphoblastic leukemia: Therapeutic advances in Childhood Leukemia Consortium (TACL 2014-001) trial.. Journal of Clinical Oncology, 2020, 38, 10512-10512.	1.6	1
100	Abstract 3234: Multi-antigen targeting of CD19, CD22 and TSLPR to prevent Ph-like ALL resistance. , 2020, , .		1
101	Transcriptomic Features of Immune Exhaustion and Senescence Predict Outcomes and Define Checkpoint Blockade-Unresponsive Microenvironments in Acute Myeloid Leukemia. Blood, 2021, 138, 223-223.	1.4	1
102	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). Blood, 2020, 136, 44-45.	1.4	1
103	Minimal residual disease comparison between Ig/TCR PCR versus NGS assays in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: A report from the COG AALL1631 study.. Journal of Clinical Oncology, 2022, 40, 10023-10023.	1.6	1
104	Approach to Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S6-S8.	0.4	0
105	Are we ABL to do better for children with BCRâ€"ABL1-like acute lymphocytic leukaemia?. Lancet Haematology,the, 2021, 8, e6-e8.	4.6	0
106	Phat Mass and Ph-like ALL: A Link Between Obesity and CRLF2 Rearrangements?. , 2021, 18, .		0
107	Mortality and Resource Utilization in Children with De Novo Acute Myeloid Leukemia Treated with Chemotherapy and Gemtuzumab Ozogamicin in the United States. Blood, 2012, 120, 4283-4283.	1.4	0
108	Abstract 2438: Genome-wide screen reveals a role for glucocorticoids in B cell development that can be exploited to improve treatment of B cell acute lymphoblastic leukemia. , 2016, , .		0

#	Article	IF	Citations
109	Preclinical Development of a T-Cell ALL CAR Demonstrates That Differences in CAR Membrane Distribution May Impact Efficacy. Blood, 2016, 128, 4019-4019.	1.4	0
110	Inhibiting pathways involved in Bâ€cell development enhances sensitivity of Bâ€cell acute lymphoblastic leukemia to glucocorticoids. FASEB Journal, 2017, 31, .	0.5	0
111	Abstract 2280: Systematic analysis of causal noncoding mutations in pediatric B-cell acute lymphoblastic leukemia. , 2018, , .		0
112	Abstract B62: Immune gene expression profiling identifies predictors of relapse in childhood acute myeloid leukemia. , 2018, , .		0
113	Immunophenotypic and Genetic Overlap between JMML and CMML. Blood, 2018, 132, 1803-1803.	1.4	0
114	PI3KÎ´ Inhibition Enhances Sensitivity of Primary High-Risk Childhood B-Cell Acute Lymphoblastic Leukemia Cells to Glucocorticoid Chemotherapy. Blood, 2019, 134, 2572-2572.	1.4	0
115	DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A-Rearranged Acute Lymphoblastic Leukemia. Blood, 2019, 134, 2742-2742.	1.4	0
116	Glucocorticoids Regulate the Splicing Factor MBNL1, a Potential Control Point for B-Cell Specification. Blood, 2019, 134, 2478-2478.	1.4	0
117	Abstract B63: Immune gene expression profiling of acute myeloid leukemia identifies predictors of survival and actionable targets for treatment. , 2020, , .		0
118	Abstract 3893: Novel synergistic targets for combination therapy in Philadelphia chromosome-like acute lymphoblastic leukemia. , 2020, , .		0
119	Abstract 5120: Surveying the AML surfaceome for novel immunotherapeutic targets. , 2020, , .		0
120	Ph-Like ALL: Diagnosis and Management. Hematologic Malignancies, 2021, , 235-247.	0.2	0
121	Reducing Dependence on General Anesthesia for Pediatric Oncology Outpatients Undergoing Repeated Lumbar Punctures. Blood, 2020, 136, 9-10.	1.4	0